Journal article icon

Journal article

Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis

Abstract:

The loss of muscle function seen in myasthenia gravis and in the animal model of the disease, experimental autoimmune myasthenia gravis (EAMG) is in part due to the activation of complement by anti-acetylcholine receptor (AChR) antibodies at the motor end-plate. In this study we describe the effects of a soluble recombinant form of human complement receptor 1 (sCR1) on the development of clinical disease and receptor loss in EAMG induced passively by administr...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Role:
Author
Publisher:
Elsevier
Journal:
Journal of Neuroimmunology More from this journal
Volume:
71
Issue:
1-2
Pages:
173-177
Publication date:
1997-11-07
Acceptance date:
1996-07-31
DOI:
ISSN:
0165-5728
Language:
English
Keywords:
Pubs id:
pubs:1025961
UUID:
uuid:cce49dea-7730-43d7-94f3-8c7061a5ad9e
Local pid:
pubs:1025961
Source identifiers:
1025961
Deposit date:
2019-07-02

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP